Amgen Inc. (NASDAQ:AMGN) Shares Bought by New England Research & Management Inc.

New England Research & Management Inc. increased its position in Amgen Inc. (NASDAQ:AMGN) by 31.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,574 shares of the medical research company’s stock after buying an additional 2,510 shares during the quarter. Amgen comprises approximately 1.6% of New England Research & Management Inc.’s holdings, making the stock its 12th largest position. New England Research & Management Inc.’s holdings in Amgen were worth $3,407,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of AMGN. Hershey Financial Advisers LLC bought a new stake in shares of Amgen during the 2nd quarter worth $30,000. nVerses Capital LLC purchased a new position in Amgen in the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC acquired a new stake in Amgen during the 2nd quarter worth about $33,000. FSA Wealth Management LLC lifted its stake in Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after buying an additional 91 shares in the last quarter. Finally, Western Pacific Wealth Management LP lifted its stake in Amgen by 27.6% during the first quarter. Western Pacific Wealth Management LP now owns 162 shares of the medical research company’s stock valued at $46,000 after buying an additional 35 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN traded down $2.21 on Monday, hitting $317.45. The company’s stock had a trading volume of 1,261,193 shares, compared to its average volume of 2,488,611. The company has a 50 day moving average price of $327.28 and a 200 day moving average price of $309.48. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a market capitalization of $170.29 billion, a PE ratio of 45.35, a PEG ratio of 2.98 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same quarter last year, the business posted $5.00 earnings per share. The business’s quarterly revenue was up 20.1% compared to the same quarter last year. On average, research analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 2.84%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is 128.57%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Bank of America boosted their price target on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 price target (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Morgan Stanley reduced their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average target price of $326.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.